氨基观察-创新药组原创出品作者 | 沙晓威一场围绕三抗的资本盛宴已然开席。7月,艾伯维宣布以7亿美元首付款收购IGI Therapeutics开发的一款三抗,靶点覆盖CD3、CD38和BCMA,用于多发性骨髓瘤(MM)治疗。这是继2025年1月与先声药业达成GPRC5D/BCMA/CD3三抗SIM0500的10.55亿美元合作之后,艾伯维在血液瘤领域的又一次出手。短短半年,豪掷17亿美元,艾伯维对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.